Research across Cancer
Related studies from across the Cancer family.
32 trials tracked for skin melanoma: 2 in phase 3 or 4.
Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
New evidence includes the implementation of AI-based Computer-Aided Diagnosis (CAD) Software for skin lesion analysis 1.
Treatment with bevacizumab has been evaluated in multiple studies, including a trial reporting a tumor response rate of 23.8% to 33.3% and progression-free survival at 6 months ranging from 32.8% to 56.1% [14, 16].
Aldesleukin was evaluated in several trials; one study showed a significant increase in tumor-antigen-specific immunity in sentinel immunized nodes (SIN) by Elispot assay (p=0.004), while no significant difference was found in peripheral blood mononuclear cells (PBMC) [18, 21, 22].
Interleukin-2 treatment demonstrated a statistically significant improvement in 5-year relapse-free survival (47% vs 38%, p=0.02), though no significant difference was found in 5-year overall survival (56% vs 56%, p=0.49) 3.
The IC-Green KIT was evaluated in a Phase 3 trial 2.
AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Cancer family.